Pharming Group (PHAR) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.30
- Estimate
- $0.21
- Surprise
- +46.3%
- Revenue (period 2026-09-30)
- $117.6M
- Score at report (before → after)
- 5.8 → 5.3/10
Revenue source: yfinance_provisional (provisional — SEC XBRL not yet filed for this period).
How the report landed
Pharming Group (PHAR) beat the $0.21 estimate with adjusted EPS of $0.30 — a large 46.3% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.8/10) to Hold at 5.3/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates PHAR Hold at 6.1/10.
2 of the last 4 quarters beat the estimate; this quarter's +46.3% surprise compares with a -372.6% four-quarter average.
What supports the rating
- Strong growth profile
- Analyst upside: 147%
What argues against it
- Negative momentum
- Below 200-MA, MA slope -7.2%/30d (confirmed downtrend)
- Momentum score 2.9/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $12.30
- Price target
- $30.35
- Stop
- $11.44
- Upside to target
- +146.7%
- Reward-to-risk
- 9.8:1
Forward estimates sit below the trailing run-rate (69.9× forward vs 39.3× trailing) — consensus expects earnings to decline from here.
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
PHAR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $891.1M
- P/E (fwd)
- 69.9
- P/E (ttm)
- 39.3
- 52-week range
- $9.11–$21.34
- Off 52-week high
- 42.4%
- RSI (14)
- 51
- Volume vs avg
- 0.45×
- Score today
- 6.1/10